Ventyx Biosciences, Inc.

For inclusion in 2023’s list , an asset had to be wholly owned, outside of clinical trial collaborations or small, regional tie-ups, and its developer unlikely to want to launch alone. The table was

There are a few candidates with the potential to join Bristol Myers Squibb Company ’s Sotyktu in the TYK2 inhibitor space but Ventyx Biosciences, Inc. 's VTX958 is no longer one of them. The San Die

Biopharma initial public offerings may be on the rise in 2024 – and not just in the US, where much of the industry’s IPO-tracking attention is focused. Galderma S.A. revealed on 6 March that it inte

Following on Bristol Myers Squibb Company ’s US Food and Drug Administration approval of the first-in-class TYK2 inhibitor Sotyktu (deucravacitinib) for moderate-to-severe plaque psoriasis in late 20